Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Status:
Terminated
Trial end date:
2017-04-19
Target enrollment:
Participant gender:
Summary
This study is an open label, single institution, Phase 1 dose-escalation study to determine
the safety profile of cetuximab-IRDye800 used in subjects with head and neck squamous cell
carcinoma (HNSCC) that undergo surgery with curative intent. Participants will be given a
dose of an approved head and neck cancer drug (Cetuximab) along with an investigational study
drug called Cetuximab-IRDye800. Cetuximab-IRDye800 is a drug that is given prior to surgery
that attaches to cancer cells and appears to make them visible to the doctor when he uses a
special camera during the operation. The investigators are evaluating whether or not the use
of the study drug along with the special camera will better identify the cancer while
patients are in the operating room.